KAM
NKTR icon

Kazazian Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Kazazian Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-573
Closed -$524K – 75
2018
Q3 		$524K Hold
573
– – 0.49% 45
2018
Q2 		$420K Sell
573
-544
-49% -$627K 0.39% 53
2018
Q1 		$1.78M Sell
1,117
-184
-14% -$237K 1.87% 16
2017
Q4 		$1.17M Buy
+1,301
New +$770K 1.19% 22
2016
Q1 		– Sell
-885
Closed -$224K – 67
2015
Q4 		$224K Sell
885
-1,805
-67% -$371K 0.3% 38
2015
Q3 		$442K Buy
2,690
+223
+9% +$39.4K 0.56% 36
2015
Q2 		$463K Buy
+2,467
New +$425K 0.46% 33

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kazazian Asset Management's NKTR Position: Q4 2018 in Review

Kazazian Asset Management sold out of Nektar Therapeutics (NKTR) in Q4 2018, closing a stake of 573 shares — an estimated $524K sold.

Kazazian Asset Management first reported a position in NKTR in Q2 2015 and held it in 7 quarters. The position peaked at $1.78M in Q1 2018. 343 funds tracked by Wall St. Rank hold NKTR as of Q4 2018.

  • Kazazian Asset Management reported no remaining Nektar Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Kazazian Asset Management sold 573 Nektar Therapeutics shares in Q4 2018, an estimated $524K.
  • Kazazian Asset Management first reported a position in Nektar Therapeutics in Q2 2015 and held it in 7 quarters.
  • Kazazian Asset Management's Nektar Therapeutics position peaked at $1.78M in Q1 2018.
  • 343 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2018.

Based on Kazazian Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.